AU2017218415B2 - Novel anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections - Google Patents

Novel anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections Download PDF

Info

Publication number
AU2017218415B2
AU2017218415B2 AU2017218415A AU2017218415A AU2017218415B2 AU 2017218415 B2 AU2017218415 B2 AU 2017218415B2 AU 2017218415 A AU2017218415 A AU 2017218415A AU 2017218415 A AU2017218415 A AU 2017218415A AU 2017218415 B2 AU2017218415 B2 AU 2017218415B2
Authority
AU
Australia
Prior art keywords
lam
antibody
seq
ser
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017218415A
Other languages
English (en)
Other versions
AU2017218415A1 (en
Inventor
Alok Choudhary
Abraham Pinter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Publication of AU2017218415A1 publication Critical patent/AU2017218415A1/en
Application granted granted Critical
Publication of AU2017218415B2 publication Critical patent/AU2017218415B2/en
Priority to AU2024205286A priority Critical patent/AU2024205286A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56933—Mycoplasma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
AU2017218415A 2016-02-10 2017-02-01 Novel anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections Active AU2017218415B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024205286A AU2024205286A1 (en) 2016-02-10 2024-08-01 Novel anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662293406P 2016-02-10 2016-02-10
US62/293,406 2016-02-10
PCT/US2017/016058 WO2017139153A1 (en) 2016-02-10 2017-02-01 Novel anti-lam and anti-pim6/lam monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024205286A Division AU2024205286A1 (en) 2016-02-10 2024-08-01 Novel anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections

Publications (2)

Publication Number Publication Date
AU2017218415A1 AU2017218415A1 (en) 2018-09-27
AU2017218415B2 true AU2017218415B2 (en) 2024-05-02

Family

ID=59563993

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017218415A Active AU2017218415B2 (en) 2016-02-10 2017-02-01 Novel anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections
AU2024205286A Pending AU2024205286A1 (en) 2016-02-10 2024-08-01 Novel anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024205286A Pending AU2024205286A1 (en) 2016-02-10 2024-08-01 Novel anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections

Country Status (10)

Country Link
US (4) US10729771B2 (enExample)
EP (2) EP4299072A3 (enExample)
JP (4) JP2019506412A (enExample)
CN (2) CN110092830B (enExample)
AU (2) AU2017218415B2 (enExample)
CA (1) CA3013904C (enExample)
ES (1) ES2970828T3 (enExample)
RU (1) RU2732502C2 (enExample)
WO (1) WO2017139153A1 (enExample)
ZA (3) ZA201805990B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2732502C2 (ru) 2016-02-10 2020-09-18 Ратгерс, Де Стейт Юниверсити Оф Нью Джерси Новые моноклональные антитела к LAM и PIM6/LAM для диагностики и лечения инфекций, вызванных Mycobacterium tuberculosis
US10830760B2 (en) 2017-12-20 2020-11-10 General Electric Company Device for rapid detection of tuberculosis-lipoarabinomannan (TB-LAM) with enhanced sensitivity
JP2021521462A (ja) * 2018-03-29 2021-08-26 ファウンデーション オブ イノベーティブ ニュー ダイアグノスティクス 抗体または抗体の組み合わせおよび対象の尿試料中のマイコバクテリウム関連抗原の検出のためのその使用
EP3823670A4 (en) * 2018-07-19 2022-04-20 Rutgers, the State University of New Jersey METHODS FOR DUAL DETECTION AND DIFFERENTIATION OF INFECTIONS WITH MYCOBACTERIUM TUBERCULOSIS COMPLEX AND NON-TUBERCULOUS MYCOBACTERIA
EP3845903A4 (en) 2018-08-31 2021-11-24 FUJIFILM Corporation IMMUNOCHROMATOGRAPHY KIT AND METHOD FOR DETECTION OF MYCOBACTERIUM TUBERCULOSIS
EP4040155B1 (en) 2019-09-30 2024-11-27 FUJIFILM Corporation Immunochromatography
EP4040151B1 (en) 2019-09-30 2025-08-13 FUJIFILM Corporation Immunological test method
CN111337665A (zh) * 2020-01-16 2020-06-26 卢氏实验室公司 一种用于检测肺结核感染的免疫层析试纸条及其制备方法
JP7740995B2 (ja) 2020-01-31 2025-09-17 富士フイルム株式会社 免疫検査方法
EP4099013A4 (en) 2020-01-31 2023-02-15 FUJIFILM Corporation IMMUNOCHROMATOGRAPHY
JP7350100B2 (ja) 2020-01-31 2023-09-25 富士フイルム株式会社 イムノクロマトグラフィー
CN111153992A (zh) * 2020-02-21 2020-05-15 首都医科大学附属北京胸科医院 结核分枝杆菌lam的单克隆抗体及其用途
US20230258633A1 (en) * 2020-07-07 2023-08-17 The Regents Of The University Of California Method for antigen detection from direct clinical samples
CN116669707B (zh) * 2020-08-05 2025-11-14 杜兰教育基金管理委员会 体液样品中结核的检测方法
EP4212873A4 (en) 2020-09-11 2024-06-05 FUJIFILM Corporation CONCENTRATION DEVICE, METHOD FOR CONCENTRATING A SAMPLE SOLUTION, METHOD FOR TESTING A SAMPLE SOLUTION AND TEST KIT
WO2022054524A1 (ja) 2020-09-11 2022-03-17 富士フイルム株式会社 濃縮デバイス、検体液の濃縮方法、検体液の検査方法、及び、検査キット
EP4212876B1 (en) 2020-09-11 2025-05-14 FUJIFILM Corporation Liquid specimen concentration method, and liquid specimen inspection method
WO2022081716A1 (en) * 2020-10-13 2022-04-21 Accubit LLC - Biotechnology Methods of treating iga nephropathy with thiol-containing molecules
EP4263598A4 (en) * 2020-12-15 2025-04-09 Albert Einstein College of Medicine High-affinity mycobacterium tuberculosis capsule-specific human monoclonal antibodies
CN113480659B (zh) * 2021-06-30 2022-10-21 迪比康(上海)生物科技有限公司 人源抗结核分枝杆菌复合群lam单克隆抗体及其制备和应用
CN114984870A (zh) * 2022-03-15 2022-09-02 齐欣 一种重组蛋白质微球及其制备方法和应用
CN117247450B (zh) * 2023-10-10 2025-02-25 广州市雷德生物科技有限公司 一种lam抗体及其应用
CN118178640B (zh) * 2024-03-08 2025-11-21 中国农业大学 含有牛分枝杆菌表面多糖的佐剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130309237A1 (en) * 2011-01-24 2013-11-21 Dso National Laboratories Pathogenic Mycobacteria-Derived Mannose-Capped Lipoarabinomannan Antigen Binding Proteins
EP2821415A1 (en) * 2012-02-29 2015-01-07 Otsuka Pharmaceutical Co., Ltd. Anti-lipoarabinomannan antibody and immunoassay for mycobacteriosis using said antibody

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4636524A (en) 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
EP0729353B2 (en) 1993-11-19 2012-09-12 Alkermes, Inc. Preparation of biodegradable microparticles containing a biologically active agent
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US20010007660A1 (en) * 1997-06-04 2001-07-12 Aharona Glatman-Freedman Methods of treating and protecting against tuberculosis using a monoclonal antibody selective for mycobacterium tuberculosis
US6573238B2 (en) 1997-11-07 2003-06-03 Chiron Corporation Method for producing sustained-release formulations
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6953593B2 (en) 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
AU2002248792B2 (en) 2001-04-18 2006-09-21 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
US7063725B2 (en) 2002-10-21 2006-06-20 Sdgi Holdings, Inc. Systems and techniques for restoring and maintaining intervertebral anatomy
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
US20050187631A1 (en) 2004-01-27 2005-08-25 Sdgi Holdings, Inc. Prosthetic device
AP2316A (en) * 2004-07-20 2011-11-04 Chemogen Inc Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same.
CN101216491B (zh) * 2008-01-08 2012-06-06 广州益善生物技术有限公司 结核分枝杆菌检测液相芯片及其制备方法
WO2009105150A2 (en) * 2008-01-28 2009-08-27 Thomas Jefferson University Method of making hybrid cells that express useful antibodies
KR20110057245A (ko) 2008-09-19 2011-05-31 메디뮨 엘엘씨 Ｃｄ105에 대해 지시된 항체 및 그의 용도
WO2011013698A1 (ja) * 2009-07-29 2011-02-03 東亞合成株式会社 キャリアペプチドフラグメント及びその利用
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
RU2732502C2 (ru) 2016-02-10 2020-09-18 Ратгерс, Де Стейт Юниверсити Оф Нью Джерси Новые моноклональные антитела к LAM и PIM6/LAM для диагностики и лечения инфекций, вызванных Mycobacterium tuberculosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130309237A1 (en) * 2011-01-24 2013-11-21 Dso National Laboratories Pathogenic Mycobacteria-Derived Mannose-Capped Lipoarabinomannan Antigen Binding Proteins
EP2821415A1 (en) * 2012-02-29 2015-01-07 Otsuka Pharmaceutical Co., Ltd. Anti-lipoarabinomannan antibody and immunoassay for mycobacteriosis using said antibody

Also Published As

Publication number Publication date
JP2023075196A (ja) 2023-05-30
CN110092830B (zh) 2023-07-04
US11707525B2 (en) 2023-07-25
RU2018131622A (ru) 2020-03-10
BR112018016226A8 (pt) 2023-10-24
AU2024205286A1 (en) 2024-08-22
US20200316199A1 (en) 2020-10-08
EP3414573B1 (en) 2023-11-08
EP4299072A3 (en) 2024-05-01
JP2021105034A (ja) 2021-07-26
RU2732502C2 (ru) 2020-09-18
ZA201805990B (en) 2023-01-25
BR112018016226A2 (pt) 2019-01-02
US11273220B2 (en) 2022-03-15
AU2017218415A1 (en) 2018-09-27
JP2019506412A (ja) 2019-03-07
WO2017139153A1 (en) 2017-08-17
ES2970828T3 (es) 2024-05-30
US20220168420A1 (en) 2022-06-02
ZA202307912B (en) 2025-11-26
EP3414573A1 (en) 2018-12-19
JP7316685B2 (ja) 2023-07-28
US12303562B2 (en) 2025-05-20
CN110092830A (zh) 2019-08-06
RU2018131622A3 (enExample) 2020-04-13
US10729771B2 (en) 2020-08-04
ZA202209045B (en) 2023-12-20
EP4299072A2 (en) 2024-01-03
US20240307535A1 (en) 2024-09-19
US20190038747A1 (en) 2019-02-07
CN109073649A (zh) 2018-12-21
CA3013904A1 (en) 2017-08-17
CA3013904C (en) 2023-12-12
EP3414573A4 (en) 2019-10-30
JP2024174883A (ja) 2024-12-17

Similar Documents

Publication Publication Date Title
AU2017218415B2 (en) Novel anti-LAM and anti-PIM6/LAM monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections
CN110914299B (zh) 抗icos促效剂抗体和其用途
AU2017228055B2 (en) Antibodies specific to human poliovirus receptor (PVR)
DK2703486T3 (en) ANTI-B7-H3 ANTIBODY
JP5586952B2 (ja) 腸球菌に対する殺活性を有するヒトの結合分子及びその使用方法
CN110831973B (zh) 多特异性抗体及其制备和使用方法
AU2017299858B2 (en) Antibodies to Amyloid beta
AU2016356686A1 (en) Anti-PD-1 antibodies and therapeutic uses thereof
TW201333038A (zh) ＰＤＧＦ受體β結合多肽
TW202300524A (zh) 用於移除造血幹細胞的抗體藥物結合物
JP7368670B2 (ja) 破傷風毒素に対する完全天然型ヒト中和モノクロナル抗体及びその応用
TW202124432A (zh) 使用pd-1軸抑制劑及抗骨膜蛋白抗體治療癌症之方法
CN116368222A (zh) 破坏cd28-唾液酸糖苷配体复合物以增强t细胞活化
WO2021091815A1 (en) Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
RU2837770C2 (ru) Мультиспецифические антитела и способы их получения и применения
JP2025510783A (ja) 抗ｃｄ９４抗体及びその使用方法
BR112018016226B1 (pt) Anticorpo antilipoarabinomanana (anti-lam) monoclonal, kit para detectar um epítopo de lam, método in vitro para diagnosticar uma infecção de tuberculose ativa em um indivíduo e método in vitro de pré-concentração de lam a partir de uma amostra biológica
KR102125672B1 (ko) 항 ｂ７-ｈ３항체
HK40007669A (en) IFN-γ-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ PINTER, ABRAHAM AND CHOUDHARY, ALOK

FGA Letters patent sealed or granted (standard patent)